New hope for rare liver infection: RBD1016 trial underway
NCT ID NCT06649266
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called RBD1016 in 14 adults with chronic hepatitis D, a serious liver infection. The main goal is to see if the drug can lower the amount of virus in the blood over 60 weeks. Participants receive either RBD1016 or a placebo and visit the clinic regularly for checkups. The trial also monitors for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Infektionskliniken, Danderyds sjukhus
Stockholm, 18288, Sweden
-
Medicinsk enhet för Infektionssjukdomar, Karolinska Universitetssjukhuset Huddinge
Stockholm, 14186, Sweden